Home » Newsletters » BioWorld

BioWorld

Feb. 3, 1994

View Archived Issues

ANESTA COMPLETES IPO

MONSANTO TO LAUNCH RBGH POSILAC

MICROCARB MAY DEVELOP HUGHES' ANTIVIRAL COMPOUNDS

IMMUNOGEN CLOSING $11.1M OFFERING

VIMRX OFFERING RAISES $5.6M

UBI'S HIV VACCINE ENTERS PHASE I CLINICALS

PROCYTE COMPLETES $33M FOLLOW-ON OFFERING

LONDON STOCK EXCHANGE TO REVIEW BIOTECH RULES

GENPHARM DENIES STEALING CELL GENESYS TECHNOLOGY

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.